MTOR and primary peritoneal carcinoma: Precision medicine, in which combinations of PIK3CA, TP53 and ATM mutations in PPC are identified and PI3K/Akt/mTOR pathway inhibitors or ICIs are administered according to the mutations pattern, may become an effective treatment for PPC with PIK3CA mutations in the future.